Pulse Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Pulse Biosciences, Inc. (PLSE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $14.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $9.00M.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $5.60M, a 700.00% increase year-over-year.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $0.00.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $700.00K.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $7.30M, a 265.00% increase from fiscal 2024.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.00M.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.60M, a 60.00% increase from fiscal 2019.
- Pulse Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $1.00M, a 44.44% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|
| 2026-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.60M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.60M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $7.30M 10-K · filed 2026-02-19 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $700.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $700.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $2.00M 10-K · filed 2026-02-19 | ||
| 2020-12-31 | $1.60M 10-K · filed 2021-03-12 | ||
| 2019-12-31 | $1.00M 10-K · filed 2021-03-12 | ||
| 2018-12-31 | $1.80M 10-K · filed 2021-03-12 | ||
| 2017-12-31 | $3.80M 10-K · filed 2020-03-16 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-14 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |